88IV - PR Newswire Asia's news - Medical/Pharmaceuticals

< Previous page

| Title only | Print

Next page >

WuXi AppTec Delivers Strong H1 2026 Results and Raises Full-Year Guidance[1], Driven by Greater Success of Multiple Customers' Products and CRDMO Model SHANGHAI , Aug. 3, 2026 /PRNewswire/ -- WuXi AppTec (stock code: 603259.SH / 2359.HK), a leading global pharmaceutical CRDMO (Contract Research, Development, and Manufacturing Organization), today announced ... 2026-08-03T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
New Chemotherapy-Free Immunotherapy Combination for Follicular Lymphoma Listed on the PBS Minjuvi ® (tafasitamab), in combination with rituximab and lenalidomide, is the first and only chemotherapy-free CD19 and CD20 dual-targeted immunotherapy combination regimen listed on the Pharmaceutical ... 2026-08-02T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
Ridgetech, Inc. Reports Fiscal Year 2026 Financial Results HANGZHOU, China , July 31, 2026 /PRNewswire/ -- Ridgetech, Inc. (Nasdaq: RDGT) ("Ridgetech" or the "Company"), a wholesale distributor of pharmaceutical and other healthcare products ... 2026-07-31T Health Care/Hospital Medical/Pharmaceuticals
Ractigen Therapeutics Announces U.S. FDA IND Clearance for First-in-Class saRNA Candidate RAG-1C to Treat Proliferative Vitreoretinopathy RAG-1C achieves dual IND clearances from both U.S. FDA and China CDE, paving the way for global clinical development of the world's first saRNA therapy for ocular diseases RAG-1C utilizes Ractigen's ... 2026-07-31T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
IMPACT Therapeutics Signs Exclusive License Agreement with Pharmanovia for Senaparib in Europe, Middle East and North Africa, Australia and New Zealand SHANGHAI , July 31, 2026 /PRNewswire/ -- IMPACT Therapeutics ("IMPACT") (07630.HK) is pleased to announce that it has entered into an exclusive partnership (the "Exclusive Partnership") ... 2026-07-31T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
CellOrigin Unveils Two Novel Solid-Tumor Cell Therapy Candidates at ASCO 2026, Partners with Walvax for In Vivo CAR Clinical Trial HANGZHOU, China , July 31, 2026 /PRNewswire/ -- CellOrigin, a biotechnology company focused on next-generation in vivo and in vitro cell therapy technologies, has announced two major progresses in ... 2026-07-31T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
Amorepacific Holdings Signs Strategic Investment Agreement with HIGHER Corporation on Beauty and Medical Aesthetics Collaboration Partnership to explore solutions connecting Amorepacific's skin science with HIGHER Corporation's medical aesthetics expertise ... 2026-07-31T Cosmetics & Personal Care Health Care/Hospital Household/Consumer/Cosmetics Medical/Pharmaceuticals
Telix H1 2026 Results: Investor Webcast Notification MELBOURNE, Australia and INDIANAPOLIS, July 31, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today advises that it will release its financial results ... 2026-07-31T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
Kuching to Host Asia's Leading Diabetes Experts at "Diabetes Asia 2026" Conference (DAC 2026) KUCHING, Malaysia , July 30, 2026 /PRNewswire/ -- As diabetes continues to place an increasing burden on Malaysia's healthcare system — affecting an estimated 4.75 million Malaysian adults - Kuching ... 2026-07-30T Health Care/Hospital Medical/Pharmaceuticals Publishing/Information Service
AiRISTA Receives Frost & Sullivan's 2026 North American Competitive Strategy Leadership Recognition for Healthcare Real-Time Location Solutions The company's interoperable RTLS platform, customer-centric strategy, and continuous innovation are transforming healthcare asset management and operational efficiency. ... 2026-07-30T Computer Software Health Care/Hospital Medical Equipment Medical/Pharmaceuticals

< Previous page

Next page >

88iv | Home | Login

Forum rule | About Us | Contact Info | Terms & Conditions | Privacy Statment | Disclaimer

Copyright (C) 2026

Suntek Computer Systems Limited.

All rights reserved